SUD patients commonly exhibit acute depressive and anxiety symptoms during the withdrawal and early recovery phases, which are associated with neuroendocrine dysregulation, including increased levels of adrenocorticotropic hormone (ACTH) and corticotropin-releasing factor (CRF) (40, 64). The gene discussed is CRH; the disease is Anxiety.